HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Items 301–400 of 671
Yap, J. L., Chauhan, J., Jung, K., Chen, L., Prochownik, E. V., & Fletcher, S. (2012) · MedChemComm · doi:10.1039/c2md00289b · Cited by 36
Hypoxia-inducible factors: Crosstalk between their protein stability and protein degradation
Wei, W., & Yu, X. D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.009 · Cited by 34
“NO targets Cys533 and Cys800 for S-nitrosylation modific Val802 in this domain is critical in targeting asparagine hydroxylation [28].”
BackgroundPast, Present and Future of Targeted Therapy in Solid Tumors
Palazzo, A., Iacovelli, R., & Cortesi, E. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517145 · Cited by 37
“The inhibition of the activity of a HIF-1alpha deubiquitylation enzyme that controls the removal of ubiquitin would be another new approach to inhibiting HIF-1 [163].”
BackgroundKim, B., & Forbes, N. S. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21205 · Cited by 36
“The presence of hypoxia in tumors is correlated with poor patient prognosis (Brizel et al., 1997; Harris, 2002) and is a distinctive marker that can be used as a therapeutic target (Giaccia et al., 2003; Semenza, 2003; Unruh et al., 2003).”
BackgroundReversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment
Salomon-Zimri, S., Glat, M. J., Barhum, Y., Luz, I., Boehm-Cagan, A., Liraz, O., Ben-Zur, T., Offen, D., & Michaelson, D. M. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160182 · Cited by 31
“It is composed of constituently expressed HIF1 subunits and the HIF-1 subunit, which is regulated at multiple levels [45, 46].”
BackgroundBisbakuchiols A and B, novel dimeric meroterpenoids from Psoralea corylifolia
Wu, C., Cai, X. F., Đạt, N. T., Hong, S. S., Han, A., Seo, E. K., Hwang, B. Y., Nan, J., Lee, D., & Lee, J. J. (2007) · Tetrahedron Letters · doi:10.1016/j.tetlet.2007.10.059 · Cited by 33
Discovery of a new molecular probe ML228: An activator of the hypoxia inducible factor (HIF) pathway
Thériault, J. R., Felts, A. S., Bates, B. S., Perez, J. R., Palmer, M. A. J., Gilbert, S. R., Dawson, E. S., Engers, J. L., Lindsley, C. W., & Emmitte, K. A. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.077 · Cited by 33
Hall, J. E., Lawrence, E. S., Simonson, T. S., & Fox, K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00471 · Cited by 34
“Given the HIF pathway has been implicated as a master transcriptional regulator of hypoxic response on an evolutionary time scale as far back as metazoans (Semenza, 1999; Giaccia et al., 2003; Wenger et al., 2005; Lendahl et al., 2009), these findings have been a major focus of high-altitude research.”
BackgroundSalidroside affects the Th17/Treg cell balance in aplastic anemia via the STAT3/HIF-1α/RORγt pathway
Liu, Z., Chen, L., Xiong, D., Zhan, Y., Liu, J., Ouyang, L., Chen, W., Lu, Z., Gao, T., Li, X., et al. (2023) · Redox Report · doi:10.1080/13510002.2023.2225868 · Cited by 33
Enzyme-immobilized hydrogels to create hypoxia for in vitro cancer cell culture
Dawes, C. S., Koenig, H., & Lin, C. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.03.007 · Cited by 32
Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α
Ma, J., Jiang, Y. Z., Shi, H. R., Mi, C., Li, J., Nan, J., Wu, X. Z., Lee, J. J., & Jin, X. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.005 · Cited by 36
“HIF-1α is overexpressed in many human cancers and has been associated with tumor aggressiveness, vascularity, treatment failure, and mortality (Birner et al., 2000; Giaccia et al., 2003).”
BackgroundTargeting the Loss of the von Hippel-Lindau Tumor Suppressor Gene in Renal Cell Carcinoma Cells
Sutphin, P. D., Chan, D. A., Li, J. M., Turcotte, S., Krieg, A. J., & Giaccia, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0604 · Cited by 36
“Thus, ChA3 induces cell death through a HIFdependent mechanism (16, 18).”
BackgroundSelf-citationGenetic Instability: The Dark Side of THE Hypoxic Response
To, K. K. W., Koshiji, M., Hammer, S., & Huang, E. L. (2005) · Cell Cycle · doi:10.4161/cc.4.7.1839 · Cited by 35
Down-regulation of HIF-1α by oncolytic reovirus infection independently of VHL and p53
Cho, I.-R., Koh, S. S., Min, H.-J., Park, E.-H., Ratakorn, S., Jhun, B. H., Jeong, S. H., Yoo, Y. H., Youn, H., Johnston, R. N., et al. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.84 · Cited by 35
Kang, S. Y., Deshpande, S. S., Donneys, A., Rodriguez, J. J., Nelson, N. S., Felice, P. A., Chepeha, D. B., & Buchman, S. R. (2013) · Bone · doi:10.1016/j.bone.2013.04.022 · Cited by 32
“HIFα is a ubiquitously expressed transcription factor that regulates cellular adaptation to hypoxia that is stabilized in osteoblasts in hypoxic conditions, mediating increased VEGF mRNA and protein expression [34–36].”
Li, W., Yan, J., Tian, H., Li, B., Wang, G., Sang, W., Zhang, Z., Zhang, X., & Dai, Y. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.09.006 · Cited by 32
Acute Vhl Gene Inactivation Induces Cardiac HIF-Dependent Erythropoietin Gene Expression
Marta, M.-M., Elorza, A., Soro-Arnáiz, I., Albacete-Albacete, L., Ordóñez, Á., Balsa, E., Vara-Vega, A., Vázquez, S., Esther, F., Carmen, F.-C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022589 · Cited by 37
“The ability of cells to respond to low O2 supply (hypoxia) is fundamental in numerous pathological scenarios [1].”
BackgroundJiang, M., Wang, B., Wang, C., He, B., Fan, H., Guo, T. B., Shao, Q., Gao, L., & Liu, Y. (2006) · Journal of Vascular Research · doi:10.1159/000095964 · Cited by 31
“], implying HIF-1a is an independent marker of disease prognosis, and a potential predictor for mortality risk and treatment failure [ , , , ,”
BackgroundHonokiol inhibits hypoxia-inducible factor-1 pathway
Lan, K.-L., Lan, K., Sheu, M., Chen, M., Shih, Y.-S., Hsu, F.-C., Wang, H.-M., Liu, R.-S., & Yen, S.-H. (2011) · International Journal of Radiation Biology · doi:10.3109/09553002.2011.568572 · Cited by 34
“Efforts to screen small molecules that interfere with HIF-1a signal transduction have identified several promising leads (Giaccia et al. 2003).”
BackgroundInfluentialShang, F.-F., Wang, J. Y., Xu, Q., Deng, H., Guo, H.-Y., Jin, X., Li, X., Shen, Q.-K., & Quan, Z.-S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113474 · Cited by 30
Ramamoorthy, P., & Shi, H.-L. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-51 · Cited by 32
“The protein level of HIF-1α is highly regulated by oxygen tension [9].”
BackgroundKasper, A. C., Moon, E. J., Hu, X., Park, Y., Wooten, C. M., Kim, H., Yang, W., Dewhirst, M. W., & Hong, J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.071 · Cited by 32
Metal-based glycoconjugates and their potential in targeted anticancer chemotherapy
Pettenuzzo, A., Pigot, R., & Ronconi, L. (2016) · Metallodrugs · doi:10.1515/medr-2015-0002 · Cited by 30
“In particular, its low activity in normal tissues makes it potentially selective toward tumor cells with minimal side-effects [23-25].”
BackgroundLee, Y. H., Lee, J. M., Kim, S. G., & Lee, Y. S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.054 · Cited by 31
UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer
Rezvani, K. S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101724 · Cited by 32
“Therefore, HIF-1α inhibition is a promising and effective strategy for the treatment of cancers [59].”
BackgroundChen, X., Gao, S., Wang, X., Guo, M., Cui, Y., Chen, Z., Liu, Y., & Wang, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101583 · Cited by 29
Boovanahalli, S. K., Jin, X., Jin, Y., Kim, J. H., Đạt, N. T., Hong, Y., Lee, J. H., Jung, S., Lee, K., & Lee, J. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.005 · Cited by 31
Hypoxia‐Inducible Factor‐1 as a Therapeutic Target in Endometrial Cancer Management
Seeber, L. M. S., Zweemer, R. P., Verheijen, R. H. M., & van Diest, P. J. (2010) · Obstetrics and Gynecology International · doi:10.1155/2010/580971 · Cited by 30
“Although none of these has been shown to directly and specifically target HIF1 [54, 55], they do decrease HIF-1α protein levels.”
Pharmacological effects of asiatic acid in glioblastoma cells under hypoxia
Thakor, F. K., Wan, K., Welsby, P. J., & Welsby, G. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-2965-5 · Cited by 29
“A drop in oxygen partial pressure activates transcription of hypoxia inducible factor (HIF) leading to changes in cellular metabolism due to transcription of a wide array of genes such as EGFR (epidermal growth factor receptor), VEGFR (vascular endothelial growth factor receptor), and GLUT-1 (glucose transporter-1) [9…”
Background(2003) · Oxygen Sensing · doi:10.1201/b14819-12 · Cited by 28
Guo, M. A., Ma, X., Feng, Y., Han, S., Dong, Q., Cui, M., & Zhao, Y. (2019) · The FASEB Journal · doi:10.1096/fj.201900402rr · Cited by 29
Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Gaissmaier, L., & Christopoulos, P. (2020) · Respiration · doi:10.1159/000510385 · Cited by 30
Alpha lipoic acid attenuates radiation-induced oral mucositis in rats
Kim, J. H., Jung, M. H., Kim, J. P., Kim, H., Jung, J. H., Hahm, J. R., Kang, K. M., Jeong, B. K., & Woo, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.20286 · Cited by 28
“com/oncotarget and increasing anaerobic metabolism [27, 28].”
Oncolytic adenoviruses as antiglioma agents
Jiang, H., McCormick, F. P., Lang, F. F., Gomez‐Manzano, C., & Fueyo-Margareto, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.697 · Cited by 32
Bredow, S., Falgout, M. M., March, T. H., Yingling, C. M., Malkoski, S. P., Aden, J. K., Bedrick, E. J., Lewis, J. L., & Divine, K. K. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.03.010 · Cited by 28
“They are also involved in the development of several pathological conditions, including stroke, cardiovascular disease, and cancer (Giaccia et al., 2003).”
BackgroundEngland, R., Masiá, E., Giménez, V., Lucas-Domínguez, R., & Vicent, M. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.017 · Cited by 28
Zhang, C., Wang, X., He, J., Huang, Y., Huang, Q., Qin, C., Qin, J., & Chen, L. (2022) · Aquatic Toxicology · doi:10.1016/j.aquatox.2022.106131 · Cited by 27
Regulation of Inflammation-Mediated Chronic Diseases by Botanicals
Sung, B., Prasad, S., Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2012) · Advances in botanical research · doi:10.1016/b978-0-12-394591-4.00003-9 · Cited by 33
Uno, M., Ban, H. S., & Nakamura, H. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.122 · Cited by 27
Wu, C.-A., Huang, D.-Y., & Lin, W. (2014) · Oncotarget · doi:10.18632/oncotarget.2265 · Cited by 30
Mistry, I. N., & Tavassoli, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00219 · Cited by 28
HIF gene expression in cancer therapy
Chan, D. A., Krieg, A. J., Turcotte, S., & Giaccia, A. J. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35016-7 · Cited by 26
Self-citationDomukhovska, A., Burakgazi, Z. A., Springer, M., Nafchi, B., Beary, M. C., Acquisto, A., Acquisto, J., Komarov, V., Jensen, M., Gulledge, B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115101 · Cited by 28
“…downstream effector targeting, in which case molecules inhibit HIF-1 α target genes and their products; or combination approaches, where HIF-1 α -targeted therapies are integrated, leading to the improved efficacy of conventional treatments to overcome hypoxia-induced resistance [70,99,120,121].”
Mi, C., Ma, J., Shi, H. R., Li, J., Wang, F., Lee, J. J., & Jin, X. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13273fp · Cited by 27
Takeuchi, A., Hori, M., Sato, S., Ban, H. S., Kuchimaru, T., Kizaka‐Kondoh, S., Yamori, T., & Nakamura, H. (2012) · MedChemComm · doi:10.1039/c2md20134h · Cited by 26
Kwon, D.-Y., Lee, H., Weitzel, D. H., Park, K., Lee, S. H., Lee, C.-T., Stephenson, T. N., Park, H., Fitzgerald, M. C., Chi, J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01220 · Cited by 29
Vetrovoy, O. V., Sarieva, K., Galkina, O., Eschenko, N., Lyanguzov, A. Y., Gluschenko, T. S., Tyulkova, E. I., & Rybnikova, E. A. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2681-x · Cited by 26
Ornelas, A., Welch, N., Countess, J. A., Zhou, L., Wang, R. X., Dowdell, A. S., & Colgan, S. P. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2267706 · Cited by 25
“17 HIF-α subunits are intimately regulated by oxygen availability through a family of iron-dependent enzymes, prolyl hydroxylases (PHDs), where PHD2 is the most studied.”
BackgroundNon-classical cardenolides from Calotropis gigantea exhibit anticancer effect as HIF-1 inhibitors
Zheng, Z., Zhou, Z., Zhang, Q., Zhou, X., Yang, J., Yang, M.-R., Zhu, G., Jiang, Z., Li, T., Lin, Q., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104740 · Cited by 25
Chang, K.-Y., Shen, M.-R., Lee, M.-Y., Wang, W.-L., Su, W., Chang, W., & Chen, B. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806210200 · Cited by 27
Kimura, M., Takabuchi, S., Tanaka, T., Murata, M., Nishi, K., Oda, S., Oda, T., Kanai, M., Fukuda, K., Kizaka‐Kondoh, S., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070824 · Cited by 26
Meng, L., Gan, S., Zhou, Y., Cheng, Y., Ding, Y., Tong, X., Wu, J., Hu, Y., & Yuan, A. (2018) · Biomaterials Science · doi:10.1039/c8bm00753e · Cited by 26
Hypoxia-Directed Drug Strategies to Target the Tumor Microenvironment
Hay, M. P., Hicks, K. O., & Wang, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_6 · Cited by 26
Chittiboyina, A. G., Kumar, G. M., de Carvalho, P. B., Liu, Y., Zhou, Y., Nagle, D. G., & Avery, M. A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm7011062 · Cited by 26
Yeh, L.-H., & Alayash, A. I. (2004) · Antioxidants and Redox Signaling · doi:10.1089/ars.2004.6.944 · Cited by 26
Protective Effect of Resveratrol against Hypoxia-Induced Neural Oxidative Stress
Auti, A. M., Alessio, N., Ballini, A., Dioguardi, M., Cantore, S., Scacco, S., Vitiello, A., Quagliuolo, L., Rinaldi, B., Santacroce, L., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081202 · Cited by 24
“Lack of oxygen limits energy metabolism to glycolysis and lowers the overall adenosine triphosphate (ATP) demand [9,10].”
BackgroundShieh, J.-M., Shen, C., Chang, W., Cheng, H.-C., Chan, Y.-Y., Huang, W., Chang, W., & Chen, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099242 · Cited by 24
“Loss of HIF-1a and ARNT also leads to an increased response to radiotherapy, a reduction in tumor growth, and decrease in angiogenesis in tumors transplanted into immune-deficient mice [12].”
BackgroundJin, X., Jin, H. R., Lee, D., Lee, J.-H., Kim, S. K., & Lee, J. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.104 · Cited by 25
Minimizing Skin Scarring through Biomaterial Design
Moore, A. L., Marshall, C. D., & Longaker, M. T. (2017) · Journal of Functional Biomaterials · doi:10.3390/jfb8010003 · Cited by 26
Fuse, S., Suzuki, K., Kuchimaru, T., Kadonosono, T., Ueda, H., Sato, S., Kizaka‐Kondoh, S., & Nakamura, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115207 · Cited by 24
Li, X., Yu, H., Huang, Y., Chen, Y., Wang, J., Xu, L., Zhang, F., Zhuge, Y., & Zou, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110512 · Cited by 24
Wang, P., Jiang, S., Li, Y., Luo, Q., Lin, J., Hu, L., Xu, C., Zhu, J., & Fan, L. (2020) · Biomaterials Science · doi:10.1039/d0bm00678e · Cited by 24
Bhalla, S., Evens, A. M., Prachand, S., Schumacker, P. T., & Gordon, L. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081333 · Cited by 24
“In addition to hypoxia, other physiological and pathological factors, such as cytokines, growth factors, activated oncogenes and inactivated tumor suppressors can activate HIF-1α primarily by stimulating its mRNA expression or translation [44-46].”
BackgroundTh17/Treg immunoregulation and implications in treatment of sulfur mustard gas-induced lung diseases
Iman, M., Rezaei, R., Jamalkandi, S. A., Shariati, P., Kheradmand, F., & Salimian, J. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1389646 · Cited by 25
“Digoxin 1 HIF1α Reduce the expression of HIF-1 [155] YC-1 stimulator (sGC)2 Soluble guanylyl cycle Inhibition DNA-binding activity of HIF-1 [156] Vincristine Microtubules Disrupts the microtubular system [157] Acriflavine HIF-1alpha and HIF-2alpha Preventing HIF-1α/HIF-1β dimer formation [158] Echinomycin HIF-1alpha a…”
BackgroundBoemo, M. A., & Byrne, H. M. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.10.044 · Cited by 26
Kim, I., Shin, S.-H., Lee, J. E., & Park, J. (2019) · Oncogene · doi:10.1038/s41388-019-0676-y · Cited by 23
Sheng, R., Li, S., Lin, G., Shangguan, S., Gu, Y., Qiu, N., Cao, J., He, Q., Yang, B., & Hu, Y. (2015) · RSC Advances · doi:10.1039/c5ra15191k · Cited by 25
Employing Tumor Hypoxia for Oncolytic Therapy in Breast Cancer
Chun, Y. S., Adusumilli, P. S., & Fong, Y. (2005) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-006-9004-6 · Cited by 25
“In hypoxia, HIF-1α heterodimerizes with HIF-β, forming active HIF-1 which translocates to the nucleus and binds to a core consensus sequence, 50-RCGTG-30, within the hypoxia responsive elements (HREs) of target genes [38, 42, 43].”
BackgroundWilhide, M. E., & Jones, W. K. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024968 · Cited by 23
“The central role of HIF-1 in the cellular response to hypoxia makes this factor an attractive therapeutic target for hypoxia-related pathologies (Giaccia et al., 2003).”
BackgroundInfluentialHypoxia‐Inducible Factors Per/ARNT/Sim Domains: Structure and Function
Scheuermann, T. H., Yang, J., Zhang, L., Gardner, K. H., & Bruick, R. K. (2007) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)35001-5 · Cited by 25
“While a number of agents have been shown to antagonize HIF (Giaccia et al., 2003; Semenza, 2003), almost all are believed to act indirectly.”
BackgroundTissue Biomarkers for Prostate Cancer Radiation Therapy
Tran, P. T., Hales, R. K., Zeng, J., Aziz, K., Salih, T., Gajula, R., Chettiar, S. T., Gandhi, N. S., Wild, A. T., Kumar, R., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412800792589 · Cited by 22
“HIF-1 alpha is a transcription factor that is stabilized under hypoxic conditions and induces a number of genes, such as VEGF resulting in tumor progression, angiogenesis, and metabolic changes, making it an ideal biomarker and potential therapeutic target [162].”
BackgroundZhang, C., He, J., Wang, X., Yang, Y., Huang, Q., Qiao, F., Shi, Q., Qin, J., & Chen, L. (2022) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2022.109409 · Cited by 28
Meng, Q., Sun, H., Wu, S., Familiari, G., Relucenti, M., Aschner, M., Li, X., & Chen, R. (2022) · Advanced Science · doi:10.1002/advs.202202116 · Cited by 24
Huang, X., & Zhang, W. (2023) · Small Methods · doi:10.1002/smtd.202301326 · Cited by 22
Minegishi, H., Matsukawa, T., & Nakamura, H. (2012) · ChemMedChem · doi:10.1002/cmdc.201200502 · Cited by 23
Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation
Avendaño, C., & Menéndez, J. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-444-52824-7.00009-3 · Cited by 26
Manohar, S. M., Padgaonkar, A., Jalota‐Badhwar, A., Rao, S. V., & Joshi, K. S. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.51 · Cited by 24
Radiation Sensitivity of GL261 Murine Glioma Model and Enhanced Radiation Response by Flavopiridol
Newcomb, E. W., Lymberis, S. C., Lukyanov, Y., Shao, Y., Schnee, T., Devitt, M. L., Rosenstein, B. S., Zagzag, D., & Formenti, S. C. (2005) · Cell Cycle · doi:10.4161/cc.5.1.2271 · Cited by 25
Savino, R., & Ciliberto, G. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401469 · Cited by 22
Melnikova, I. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2113 · Cited by 22
Complex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 24
Jin, M.-L., Zou, Z., Tao, T., Li, J., Xu, J., Luo, K.-J., & Liu, Z. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s238616 · Cited by 22
Combination therapy targeting cancer metabolism
Wenger, J. B., Chun, S. Y., Dang, D. T., Luesch, H., & Dang, L. H. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.09.008 · Cited by 22
“To date, high-throughput small compound screens and mechanistic studies have identified several classes of anticancer agents that disrupt HIF-1 function, including inhibition of its transcriptional activity and HIF-1α protein synthesis or stability (39, 40).”
BackgroundYang, C., Liu, H., & Liu, D. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1953 · Cited by 21
“Hypoxia-inducible factor 1 α (HIF1 α ) plays an important role in angiogenesis (1-4).”
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Barnucz, E., Veres, G., Hegedűs, P., Klein, S., Zöller, R., Radovits, T., Korkmaz, S., Horkay, F., Merkely, B. P., Karck, M., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200790 · Cited by 20
Yang, W., Sun, T., Cao, J., & Fan, S. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2011.0955 · Cited by 22
“19,20 There are at least two mechanisms mediating the effect of HIF-1 a on tumor radioresistance.”
Choi, S., Lee, K., Lee, J. H., Kang, H. J., Lee, M., Kim, H. Y., Park, K., Kim, S., Shin, H. K., & Seo, W. D. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.9.069 · Cited by 19
“Consequently, HIF-1 has been reported to have significant potential as a target for cancer therapy (10-12).”
BackgroundYang, C., Zhang, X., Yin, H., Du, Z., & Yang, Z. R. (2020) · Toxicology in Vitro · doi:10.1016/j.tiv.2020.104787 · Cited by 19
Chung, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa308 · Cited by 19
ATF5 and HIF1α cooperatively activate HIF1 signaling pathway in esophageal cancer
He, F., Xiao, H., Cai, Y., & Zhang, N. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00734-x · Cited by 20
“In normoxia, HIF1α can be prolyl-hydroxylated, and prolyl-hydroxylation of HIF1α is further regulated by various E3 ubiquitin protein ligases [7].”
BackgroundGrabe, D. W. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070182 · Cited by 19
Chen, S.-M., Li, Y., Wang, D., Zhang, G., & Chun-jiang, T. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.073 · Cited by 19
Combination Therapy for Renal Cell Cancer: What Are Possible Options?
Santos, N., Wenger, J. B., Havre, P. A., Liu, Y., Dagan, R., Imanirad, I., Ivey, A. M., Zlotecki, R. A., Algood, C. B., Gilbert, S. M., et al. (2011) · Oncology · doi:10.1159/000333470 · Cited by 20
Gaitanaki, C., Kalpachidou, T., Aggeli, I.-K. S., Papazafiri, P., & Beis, I. D. (2007) · Journal of Experimental Biology · doi:10.1242/jeb.003178 · Cited by 21
“Hypoxia is defined as a state when oxygen tension drops below normal limits, playing a pivotal role in pathological conditions including cardiovascular diseases (Giaccia et al., 2003; Jiang et al., 2007; Muir et al., 2007).”
BackgroundModulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment
Mayes, P. A., Campbell, L., Ricci, M., Plastaras, J. P., Dicker, D. T., & El‐Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2255 · Cited by 19
Asparagine Hydroxylation is a Reversible Post-translational Modification
Rodríguez, J., Haydinger, C. D., Peet, D. J., Nguyen, L. K., & von Kriegsheim, A. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.002189 · Cited by 21
“mechanism (25, 31), but this notion is only founded on the assumption that PTMs should be generally reversible.”
BackgroundTargeting the hypoxia inducible factor pathway with mitochondrial uncouplers
Thomas, R., & Kim, M. H. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9295-3 · Cited by 20
“HIF-1a and HIF-2a are overexpressed in many common human tumors when compared to the adjoining normal tissue [12] as a result of hypoxia, as well as genetic alterations.”
BackgroundTurcotte, S., Sutphin, P. D., & Giaccia, A. J. (2008) · Autophagy · doi:10.4161/auto.6785 · Cited by 22
Self-citationAmin, N., Chen, S., Ye, S., Wu, F., Hussien, A. B., Lou, C., Hu, Z., Wang, Y., Wu, J., & Fang, M. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154298 · Cited by 18
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.